Walnut Creek, CANCT04221893Now EnrollingIRB Ready

Stage IV Esophageal Adenocarcinoma Clinical Trial in Walnut Creek, CA

Access cutting-edge stage iv esophageal adenocarcinoma treatment through this clinical trial at a research site in Walnut Creek. Study-provided care at no cost to qualified participants.

Sponsored by University of California, San Francisco

Quick Self-Assessment

See if you qualify for this Walnut Creek location

Preparing your pre-screening questions…

Expert Care in Walnut Creek

Access stage iv esophageal adenocarcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related stage iv esophageal adenocarcinoma treatment provided free

Apply for This Walnut Creek Location

Check if you qualify for this stage iv esophageal adenocarcinoma clinical trial in Walnut Creek, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Walnut Creek

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Walnut Creek site if eligible
  4. 4Begin participation

About This Stage IV Esophageal Adenocarcinoma Study in Walnut Creek

This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.

Sponsor: University of California, San Francisco

Who Can Participate

Inclusion Criteria

Patients must have a histologically, cytologically, or radiographically confirmed metastatic gastrointestinal (GI) malignancy (esophageal, gastroesophageal, gastric, small intestine, hepatocellular, pancreaticobiliary, colorectal, or anal cancer).
Patients must be receiving immunotherapy (checkpoint inhibitor or CTLA4 inhibitor) with overall response of progressive disease by RECIST criteria.
Patients must have at least two metastases which are individually progressing as per RECIST criteria, one of which can be safely unirradiated as adjudicated by the treating radiation oncologist (e.g. lesions for which small increases in dimensions are unlikely to precipitate significant symptoms).
Patients must have 1-5 sites of disease meeting standard-of-care indications for palliative radiation therapy as adjudicated by the treating radiation oncologist. For example:
Symptomatic disease causing pain, bleeding, dyspnea, dysphagia, or nausea
At-risk for neurologic, respiratory, cardiovascular, gastrointestinal, musculoskeletal, or hepatobiliary compromise
Evaluation by a radiation oncologist within 28 days of study registration.
Must have adequate organ function to administer radiation therapy and immunotherapy as per standard of care.
Age \>= 18 years.
Life expectancy exceeding 6 months.
Eastern Cooperative Oncology Group (ECOG) 0-2 or Karnofsky performance status \>= 50.
Radiation therapy is known to be teratogenic and therefore women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of radiation therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for 3 months after completion of radiation therapy. Contraception requirements during the follow-up period of 6 months will be according to standard of care for immunotherapy administration. a. If a woman is of child-bearing potential, a negative pregnancy test within 28 days prior to study enrollment is required.
Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria

Enrollment on immunotherapy clinical trial for which radiation therapy is not permitted.
Administration of radiation therapy within 4 weeks prior to study enrollment.
Treatment with systemic corticosteroids or other immunosuppressive medications which would significantly diminish the effect of immunotherapy as judged by the treating physician.
Radiation therapy is contraindicated as adjudicated by the radiation oncologist.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Walnut Creek?

Yes, this clinical trial (NCT04221893) has an active research site in Walnut Creek, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Stage IV Esophageal Adenocarcinoma Treatment Options in Walnut Creek, CA

If you're searching for stage iv esophageal adenocarcinoma treatment options in Walnut Creek, CA, this clinical trial (NCT04221893) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Walnut Creek research site is actively enrolling participants for this clinical trial. You'll receive care from experienced stage iv esophageal adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all stage iv esophageal adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

More Esophageal Cancer Trials in Walnut Creek, CA

See all esophageal cancer clinical trials recruiting in Walnut Creek — not just this study.

Browse Esophageal Cancer Trials in Walnut Creek →

Browse More Trials by Condition

Esophageal Cancer TrialsAlzheimers Disease TrialsPulmonary Hypertension TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Walnut Creek?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Walnut Creek, CA